Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more ...

Jill Sisco, president of Acromegaly Community, opposes the Most Favored Nation policy that would limit rare disease patients' access to innovative therapies.

ACRO/TRUTH Provides Authentic Patient Perspectives, Peer-Reviewed Data on Treatment-Related Symptoms, Side Effects and Quality-of-Life Impact of Current Acromegaly Standard-of-Care SAN DIEGO, Aug. 08, ...

Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following ...

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting the ...

The online resource, Acromegaly.care, is an educational website that provides practical information and tools for patients and their loved ones. The website seeks to shed light on the challenges of ...

While the most obvious signs of acromegaly are changes to your facial features and unusual growth in your hands and feet, it also has effects no one else can see. This rare disease is caused by an ...

Crinetics Pharmaceuticals’ CRNX shares gained 19.1% on Mar 19 after the company reported positive top-line data from the second (PATHFNDR-2) of two late-stage studies evaluating the efficacy and ...

The US Food and Drug Administration (FDA) has approved oral octreotide (Mycapssa, Chiasma) delayed-release capsules for the long-term maintenance treatment of patients with acromegaly who previously ...

83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an Increase on Placebo (p<0.0001) After Switching from ...